These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23979710)

  • 1. Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers.
    Berg M; Guriby M; Nordgård O; Nedrebø BS; Ahlquist TC; Smaaland R; Oltedal S; Søreide JA; Kørner H; Lothe RA; Søreide K
    Mol Med; 2013 Sep; 19(1):286-93. PubMed ID: 23979710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
    Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
    Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
    J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
    de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
    Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location.
    Søreide K; Nedrebø BS; Søreide JA; Slewa A; Kørner H
    World J Surg; 2009 Dec; 33(12):2695-703. PubMed ID: 19823901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
    Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
    Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer.
    Song J; Kataoka K; Yamada T; Shiozawa M; Sonoyama T; Beppu N; Ueda K; Kuriyama S; Kanazawa A; Ikeda M; Ceelen W
    Cancer Sci; 2021 Apr; 112(4):1545-1555. PubMed ID: 33484192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.
    Morikawa T; Tanaka N; Kuchiba A; Nosho K; Yamauchi M; Hornick JL; Swanson RS; Chan AT; Meyerhardt JA; Huttenhower C; Schrag D; Fuchs CS; Ogino S
    Arch Surg; 2012 Aug; 147(8):715-23. PubMed ID: 22508672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer.
    Birgisson H; Edlund K; Wallin U; Påhlman L; Kultima HG; Mayrhofer M; Micke P; Isaksson A; Botling J; Glimelius B; Sundström M
    BMC Cancer; 2015 Mar; 15():125. PubMed ID: 25884297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials.
    Taieb J; Sinicrope FA; Pederson L; Lonardi S; Alberts SR; George TJ; Yothers G; Van Cutsem E; Saltz L; Ogino S; Kerr R; Yoshino T; Goldberg RM; André T; Laurent-Puig P; Shi Q
    Ann Oncol; 2023 Nov; 34(11):1025-1034. PubMed ID: 37619846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147.
    Gonsalves WI; Mahoney MR; Sargent DJ; Nelson GD; Alberts SR; Sinicrope FA; Goldberg RM; Limburg PJ; Thibodeau SN; Grothey A; Hubbard JM; Chan E; Nair S; Berenberg JL; McWilliams RR;
    J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24925349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.
    Fariña-Sarasqueta A; van Lijnschoten G; Moerland E; Creemers GJ; Lemmens VEPP; Rutten HJT; van den Brule AJC
    Ann Oncol; 2010 Dec; 21(12):2396-2402. PubMed ID: 20501503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.
    Cushman-Vokoun AM; Stover DG; Zhao Z; Koehler EA; Berlin JD; Vnencak-Jones CL
    Clin Colorectal Cancer; 2013 Sep; 12(3):168-78. PubMed ID: 23773459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer.
    Nitsche U; Rosenberg R; Balmert A; Schuster T; Slotta-Huspenina J; Herrmann P; Bader FG; Friess H; Schlag PM; Stein U; Janssen KP
    Ann Surg; 2012 Nov; 256(5):763-71; discussion 771. PubMed ID: 23095620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
    Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
    PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
    J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.